ARIPIPRAZOLE (Page 5 of 14)

6.1 Clinical Trials Experience

Adult Patients with Schizophrenia

The following findings are based on a pool of five placebo-controlled trials (four 4-week and one 6-week) in which oral aripiprazole was administered in doses ranging from 2 to 30 mg/day.

Commonly Observed Adverse Reactions

The only commonly observed adverse reaction associated with the use of aripiprazole in patients with schizophrenia (incidence of 5% or greater and aripiprazole incidence at least twice that for placebo) was akathisia (aripiprazole 8%; placebo 4%).

Less Common Adverse Reactions in Adults

Table 17 enumerates the pooled incidence, rounded to the nearest percent, of adverse reactions that occurred during acute therapy (up to 6 weeks in schizophrenia and upto 3 weeks in another indication), including only those reactions that occurred in 2% or more of patients treated with aripiprazole (doses ≥2 mg/day) and for which the incidence in patients treated with aripiprazole was greater than the incidence in patients treated with placebo in the combined dataset.

Table 17: Adverse Reactions in Short-Term, Placebo-Controlled Trials in Adult Patients Treated with Oral Aripiprazole
System Organ Class Preferred Term
Percentage of Patients Reporting Reaction *
Aripiprazole Placebo
(n=1843) (n=1166)
*
Adverse reactions reported by at least 2% of patients treated with oral aripiprazole, except adverse reactions which had an incidence equal to or less than placebo.
Eye Disorders
Blurred Vision 3 1
Gastrointestinal Disorders
Nausea 15 11
Constipation 11 7
Vomiting 11 6
Dyspepsia 9 7
Dry Mouth 5 4
Toothache 4 3
Abdominal Discomfort 3 2
Stomach Discomfort 3 2
General Disorders and Administration Site Conditions
Fatigue 6 4
Pain 3 2
Musculoskeletal and Connective Tissue Disorders
Musculoskeletal Stiffness 4 3
Pain in Extremity 4 2
Myalgia 2 1
Muscle Spasms 2 1
Nervous System Disorders
Headache 27 23
Dizziness 10 7
Akathisia 10 4
Sedation 7 4
Extrapyramidal Disorder 5 3
Tremor 5 3
Somnolence 5 3
Psychiatric Disorders
Agitation 19 17
Insomnia 18 13
Anxiety 17 13
Restlessness 5 3
Respiratory, Thoracic, and Mediastinal Disorders
Pharyngolaryngeal Pain 3 2
Cough 3 2

An examination of population subgroups did not reveal any clear evidence of differential adverse reaction incidence on the basis of age, gender, or race.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.